Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
After finishing at $25.19 in the prior trading day, NewAmsterdam Pharma Company NV (NASDAQ: NAMS) closed at $24.47, down -2.86%. In other words, the price has decreased by -$2.86 from its previous closing price. On the day, 0.64 million shares were traded. NAMS stock price reached its highest trading level at $25.02 during the session, while it also had its lowest trading level at $24.12.
Ratios:
Our goal is to gain a better understanding of NAMS by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 21.08 and its Current Ratio is at 21.08. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Wells Fargo on August 25, 2025, initiated with a Overweight rating and assigned the stock a target price of $45. On July 17, 2025, Goldman started tracking the stock assigning a Neutral rating and target price of $27.
On June 17, 2025, Citigroup started tracking the stock assigning a Buy rating and target price of $42.Citigroup initiated its Buy rating on June 17, 2025, with a $42 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 25 ’25 when Kooij Louise Frederika sold 8,269 shares for $24.86 per share. The transaction valued at 205,567 led to the insider holds 15,000 shares of the business.
Kooij Louise Frederika bought 8,269 shares of NAMS for $208,296 on Aug 25 ’25. On Aug 22 ’25, another insider, Kastelein Johannes Jacob Piete, who serves as the Chief Scientific Officer of the company, sold 50,000 shares for $25.14 each. As a result, the insider received 1,257,140 and left with 69,302 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NAMS now has a Market Capitalization of 2756007168 and an Enterprise Value of 2017184384. For the stock, the TTM Price-to-Sale (P/S) ratio is 43.06 while its Price-to-Book (P/B) ratio in mrq is 3.54. Its current Enterprise Value per Revenue stands at 31.516 whereas that against EBITDA is -11.686.
Stock Price History:
The Beta on a monthly basis for NAMS is -0.00, which has changed by 0.51987576 over the last 52 weeks, in comparison to a change of 0.1590569 over the same period for the S&P500. Over the past 52 weeks, NAMS has reached a high of $27.29, while it has fallen to a 52-week low of $14.06. The 50-Day Moving Average of the stock is 11.07%, while the 200-Day Moving Average is calculated to be 14.87%.
Shares Statistics:
The stock has traded on average 885.32K shares per day over the past 3-months and 767180 shares per day over the last 10 days, according to various share statistics. A total of 112.51M shares are outstanding, with a floating share count of 73.01M. Insiders hold about 35.17% of the company’s shares, while institutions hold 61.56% stake in the company. Shares short for NAMS as of 1755216000 were 7328645 with a Short Ratio of 8.28, compared to 1752537600 on 6878437. Therefore, it implies a Short% of Shares Outstanding of 7328645 and a Short% of Float of 7.76.
Earnings Estimates
Current recommendations for the stock of the company come from 11.0 analysts. The consensus estimate for the next quarter is -$0.38, with high estimates of -$0.26 and low estimates of -$0.49.
Analysts are recommending an EPS of between -$0.94 and -$1.45 for the fiscal current year, implying an average EPS of -$1.21. EPS for the following year is -$1.78, with 9.0 analysts recommending between -$1.32 and -$2.52.
Revenue Estimates
A total of 12 analysts have provided revenue estimates for NAMS’s current fiscal year. The highest revenue estimate was $46.21M, while the lowest revenue estimate was $18.99M, resulting in an average revenue estimate of $27.17M. In the same quarter a year ago, actual revenue was $43.39M
